Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Dermapharm Holding SE (DMPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.100x
Based on the latest financial reports, Dermapharm Holding SE (DMPHF) has a cash flow conversion efficiency ratio of 0.100x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($64.66 Million) by net assets ($648.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dermapharm Holding SE - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Dermapharm Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dermapharm Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermapharm Holding SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
secunet Security Networks Aktiengesellschaft
F:YSN
|
-0.011x |
|
Luenmei Quantum Co Ltd
SHG:600167
|
0.009x |
|
Allgens Medical Technology Co. Ltd. A
SHG:688613
|
-0.001x |
|
Cembre S.p.A. Ord
LSE:0DXU
|
0.104x |
|
MICROVAST HOLD. DL-0001
F:2OZA
|
N/A |
|
Mrs. Bectors Food Specialities Limited
NSE:BECTORFOOD
|
0.088x |
|
9ZX0
F:9ZX0
|
-0.118x |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
0.052x |
Annual Cash Flow Conversion Efficiency for Dermapharm Holding SE (2014–2024)
The table below shows the annual cash flow conversion efficiency of Dermapharm Holding SE from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $608.29 Million | $201.38 Million | 0.331x | -17.77% |
| 2023-12-31 | $545.05 Million | $219.42 Million | 0.403x | -25.70% |
| 2022-12-31 | $532.49 Million | $288.53 Million | 0.542x | +8.18% |
| 2021-12-31 | $499.83 Million | $250.37 Million | 0.501x | +24.02% |
| 2020-12-31 | $324.58 Million | $131.10 Million | 0.404x | +14.20% |
| 2019-12-31 | $284.49 Million | $100.61 Million | 0.354x | -43.08% |
| 2018-12-31 | $256.08 Million | $159.13 Million | 0.621x | -47.21% |
| 2017-12-31 | $73.69 Million | $86.74 Million | 1.177x | -6.78% |
| 2016-12-31 | $60.81 Million | $76.78 Million | 1.263x | +38.98% |
| 2015-12-31 | $44.44 Million | $40.38 Million | 0.909x | -43.05% |
| 2014-12-31 | $34.01 Million | $54.26 Million | 1.595x | -- |